KRAS and neoplasm: Based on single circulating tumor cell sequencing, another study reported repeated mutations in the RTK-KRAS (EGFR, KRAS, BRAF genes), TP53, and other genes in the ALK-independent pathway in crizotinib-resistant patients (160).